Diabetic Retinopathy

Diabetic Retinopathy

Combatting, restoring — naturally

Alongside Age-Related Macular Degeneration, Diabetic Retinopathy is one of the most common causes of vision loss and blindness in the developed world. It’s estimated that around 366 million people will have diabetes by 2030, and up to 44% of sufferers will develop some form of the disease.1

Main Image Landing Diabetes

Photocoagulation — the mainstream pathway

Laser photocoagulation delivered by Ellex's Integre ProTM continues to be a mainstream treatment pathway, and the importance of the approach has grown with the introduction of pattern scanning photocoagulation — exemplified within our Integre Pro ScanTM model — which transforms the efficacy and efficiency of treatment.

Retinal rejuvenation — the next step

With the development of Ellex 2RT™, which utilizes an ultra-short nanosecond laser pulse with a unique pixelated beam profile, it’s possible to effectively treat Clinically Significant Macular Edema (CSME) secondary to diabetic retinopathy, with the added benefit of sparing the photoreceptors, and therefore retinal function, from thermal damage. Using 500 times less energy than retinal photocoagulation, and without the incidence of thermal damage, 2RT™ represents a breakthrough in the laser-based treatment of CSME.1, 2

1. Pelosini L. et al., RETINA REJUVENATION THERAPY FOR DIABETIC MACULAR EDEMA A Pilot Study, Retina 0:1-11,2012

        2. Casson RJ. Et al., “Pilot randomized trial of a nanopulse retinal laser versus conventional photocoagulation for the treatment of diabetic macular oedema”, Clin Experiment Ophthalmol. 2012 Aug;40(6):604-10

        Patient Information

        Physician Resources


        primary online resource for physicians, for patient marketing and practice development materials

        Visit community.ellex.com

        Contact us

        *Not for complaints or regulatory bodies. View our Privacy Policy

        This website uses cookies to ensure you get the best experience on our website.
        The cookies do not store any personalised information. Learn More


        Quantel Medical has completed its acquisition of Ellex, including the company’s laser and ultrasound technology solutions (with the exception of 2RT® and iTrack®), via the financial holding company Lumibird Medical.

        The coming together of these two companies—both renowned in the field of ophthalmology—represents a real milestone in their history. Quantel Medical and Ellex have a shared heritage in the development of cutting-edge technologies for the diagnosis and treatment of the leading causes of blindness worldwide: glaucoma, cataracts, AMD and diabetic retinopathy.